{
  "source": "PA-Notification-Ogsiveo.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1431-2\nProgram Prior Authorization/Notification\nMedication Ogsiveo™ (nirogacestat)\nP&T Approval Date 1/2025\nEffective Date 4/1/2025\n1. Background:\nOgsiveo™ (nirogacestat) is a gamma secretase inhibitor indicated for adult patients with\nprogressing desmoid tumors who require systemic treatment.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Ogsiveo will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Desmoid Tumors\n1. Initial Authorization\na. Ogsiveo will be approved based on all of the following criteria:\n(1) Diagnosis of desmoid tumor\n-AND-\n(2) Disease is progressive\n-AND-\n(3) Patient requires systemic treatment\nAuthorization will be issued for 12 months.\n© 2025 UnitedHealthcare Services, Inc.\n1\n2. Reauthorization Criteria\na. Ogsiveo will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Ogsiveo therapy\nAuthorization will be issued for 12 months.\nC. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of\nEvidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact cover",
    "onsensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits and/or Step Therapy may be in place.\n4. References:\n1. Ogsiveo [package insert]. Stamford, CT: SpringWorks Therapeutics, Inc.; April 2024.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttps://www.nccn.org/professionals/drug_compendium/content/. Accessed November 27, 2024.\nProgram Prior Authorization/Notification - Ogsiveo (nirogacestat)\nChange Control\n1/2024 New program.\n1/2025 Annual review with no changes to coverage criteria. Updated references.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}